AU729643B2 - Polypeptide conjugates for transporting substances across cell membranes - Google Patents

Polypeptide conjugates for transporting substances across cell membranes Download PDF

Info

Publication number
AU729643B2
AU729643B2 AU29298/97A AU2929897A AU729643B2 AU 729643 B2 AU729643 B2 AU 729643B2 AU 29298/97 A AU29298/97 A AU 29298/97A AU 2929897 A AU2929897 A AU 2929897A AU 729643 B2 AU729643 B2 AU 729643B2
Authority
AU
Australia
Prior art keywords
polypeptide
acid
compound
composition
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU29298/97A
Other languages
English (en)
Other versions
AU2929897A (en
Inventor
James E Summerton
Dwight D Weller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
Antivirals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antivirals Inc filed Critical Antivirals Inc
Publication of AU2929897A publication Critical patent/AU2929897A/en
Application granted granted Critical
Publication of AU729643B2 publication Critical patent/AU729643B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU29298/97A 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes Ceased AU729643B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1634796P 1996-05-01 1996-05-01
US60/016347 1996-05-01
US2860996P 1996-10-23 1996-10-23
US60/028609 1996-10-23
PCT/US1997/007335 WO1997040854A2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes

Publications (2)

Publication Number Publication Date
AU2929897A AU2929897A (en) 1997-11-19
AU729643B2 true AU729643B2 (en) 2001-02-08

Family

ID=26688485

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29298/97A Ceased AU729643B2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes

Country Status (5)

Country Link
EP (1) EP0966303A2 (2)
JP (1) JP2000509394A (2)
AU (1) AU729643B2 (2)
CA (1) CA2252706A1 (2)
WO (1) WO1997040854A2 (2)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69829469D1 (de) * 1997-01-24 2005-04-28 Avi Biopharm Inc Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen
CA2280957A1 (en) * 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
CA2381425A1 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
AU2001271873A1 (en) 2000-07-06 2002-01-21 Avi Biopharma, Inc. Transforming growth factor beta (TGF-beta) blocking agent-treated stem cell composition and method
EP1301213B1 (en) 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems
JP2004523480A (ja) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ， インコーポレイテッド 活性作用物質送達系ならびに活性作用物質の保護および投与方法
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
BRPI0406647A (pt) 2003-01-06 2005-12-06 Angiochem Inc Método para transportar um composto através da barreira sanguìnea do cérebro
EP1713332A4 (en) 2004-01-23 2010-08-18 Avi Biopharma Inc ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
ATE510914T1 (de) 2004-07-02 2011-06-15 Avi Biopharma Inc Antisinn antibakterielle verfahren und verbindungen
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
US7557182B2 (en) 2005-02-18 2009-07-07 Angiochem Inc. Molecules for transporting a compound across the blood-brain barrier
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
CA2614191C (en) 2005-07-13 2015-06-30 Avi Biopharma, Inc. Antisense antibacterial method and compound
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
JP5436856B2 (ja) 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8754056B2 (en) 2008-03-20 2014-06-17 University Of Florida Research Foundation, Inc. Enhancing vessel lesion homing and repair potential of stem cells
EP2143726A1 (en) * 2008-07-11 2010-01-13 Novosom AG Nucleic acid comprising zwitterionic nucleotides
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2009335740B2 (en) * 2008-12-17 2016-04-21 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
MX2011012875A (es) 2009-06-05 2012-02-28 13Therapeutics Inc Peptidos inmunoreguladores y metodos de uso.
AU2010268726A1 (en) 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
KR20200133284A (ko) 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EA202090338A1 (ru) 2011-11-18 2021-04-30 Сарепта Терапьютикс, Инк. Функционально-модифицированные олигонуклеотиды и их субъединицы
JP6542662B2 (ja) 2012-03-20 2019-07-10 サレプタ セラピューティクス， インコーポレイテッド オリゴヌクレオチドアナログのボロン酸結合体
GB201210358D0 (en) * 2012-06-12 2012-07-25 Polytherics Ltd Complexes
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE DENDRIMER CONJUGATES AND ITS USES
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
KR20180105115A (ko) * 2015-10-07 2018-09-27 코르메딕스, 인코포레이티드 타우로리딘의 피부-침투성 제제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
WO1992010212A1 (en) * 1990-12-05 1992-06-25 Farmitalia Carlo Erba Srl Anthracycline-conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
DE69735057T2 (de) * 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
WO1992010212A1 (en) * 1990-12-05 1992-06-25 Farmitalia Carlo Erba Srl Anthracycline-conjugates

Also Published As

Publication number Publication date
AU2929897A (en) 1997-11-19
WO1997040854A2 (en) 1997-11-06
CA2252706A1 (en) 1997-11-06
JP2000509394A (ja) 2000-07-25
WO1997040854A3 (en) 1998-03-12
EP0966303A2 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
AU729643B2 (en) Polypeptide conjugates for transporting substances across cell membranes
US6030941A (en) Polymer composition for delivering substances in living organisms
AU2002306500B2 (en) Transporters comprising spaced arginine moieties
US6379660B1 (en) Nitric oxide-releasing 1-[(2-carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolates and composition comprising same
Christie et al. Design strategies to improve soluble macromolecular delivery constructs
JP3731899B2 (ja) 酸化窒素放出生体高分子含有医薬組成物
US6593292B1 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7169814B2 (en) Guanidinium transport reagents and conjugates
CA2205555C (en) Use of nitric oxide-releasing agents for reducing metastasis risk
US6730293B1 (en) Compositions and methods for treating inflammatory diseases of the skin
US6262253B1 (en) Vitamin B12 conjugates with gcsf, analogues thereof and pharmaceutical compositions
JP2004530657A (ja) 上皮組織にわたるおよび上皮組織への薬物送達を増強するための組成物および方法
JP2003523982A (ja) 生体膜および生体組織を横切る薬物送達を増強するための、組成物および方法
WO2000074721A1 (en) Vitamin directed dual targeting therapy
Shi et al. Intelligent “Peptide-Gathering Mechanical Arm” tames wild “Trojan-Horse” peptides for the controlled delivery of cancer nanotherapeutics
US9943606B2 (en) Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
US20030068379A1 (en) Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell
WO2024041535A1 (zh) 纳米组合物及其制备方法和用途
US20080031883A1 (en) Condition-dependent, multiple target delivery system
EP0485749A2 (en) Chemical modification of antibodies for creating of immunoconjugates
US20050220754A1 (en) Vitamin directed targeting therapy
EP4228671A1 (en) Linker compounds comprising amide bonds
Van Heeswijk et al. Synthesis, characterization and antitumor activity of macromolecular prodrugs of adriamycin
van Heeswijk et al. Dept. of Chem. Technology, Twente University of Technol-ogy, Enschede, Dept. of Internal Medicine, Free Univer-sity Hospital, Amsterdam; Radiobiological Institute TNO
US20080139670A1 (en) Drug Delivery System

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)